DNA Damage and Repair Biomarkers of Immunotherapy Response
DNA-damaging agents are widely used in clinical oncology and exploit deficiencies in tumor DNA repair. Given the expanding role of immune checkpoint blockade as a therapeutic strategy, the interaction of tumor DNA damage with the immune system has recently come into focus, and it is now clear that t...
Uložené v:
| Vydané v: | Cancer discovery Ročník 7; číslo 7; s. 675 |
|---|---|
| Hlavní autori: | , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.07.2017
|
| Predmet: | |
| ISSN: | 2159-8290, 2159-8290 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | DNA-damaging agents are widely used in clinical oncology and exploit deficiencies in tumor DNA repair. Given the expanding role of immune checkpoint blockade as a therapeutic strategy, the interaction of tumor DNA damage with the immune system has recently come into focus, and it is now clear that the tumor DNA repair landscape has an important role in driving response to immune checkpoint blockade. Here, we summarize the mechanisms by which DNA damage and genomic instability have been found to shape the antitumor immune response and describe clinical efforts to use DNA repair biomarkers to guide use of immune-directed therapies.
Only a subset of patients respond to immune checkpoint blockade, and reliable predictive biomarkers of response are needed to guide therapy decisions. DNA repair deficiency is common among tumors, and emerging experimental and clinical evidence suggests that features of genomic instability are associated with response to immune-directed therapies. |
|---|---|
| AbstractList | DNA-damaging agents are widely used in clinical oncology and exploit deficiencies in tumor DNA repair. Given the expanding role of immune checkpoint blockade as a therapeutic strategy, the interaction of tumor DNA damage with the immune system has recently come into focus, and it is now clear that the tumor DNA repair landscape has an important role in driving response to immune checkpoint blockade. Here, we summarize the mechanisms by which DNA damage and genomic instability have been found to shape the antitumor immune response and describe clinical efforts to use DNA repair biomarkers to guide use of immune-directed therapies.
Only a subset of patients respond to immune checkpoint blockade, and reliable predictive biomarkers of response are needed to guide therapy decisions. DNA repair deficiency is common among tumors, and emerging experimental and clinical evidence suggests that features of genomic instability are associated with response to immune-directed therapies. DNA-damaging agents are widely used in clinical oncology and exploit deficiencies in tumor DNA repair. Given the expanding role of immune checkpoint blockade as a therapeutic strategy, the interaction of tumor DNA damage with the immune system has recently come into focus, and it is now clear that the tumor DNA repair landscape has an important role in driving response to immune checkpoint blockade. Here, we summarize the mechanisms by which DNA damage and genomic instability have been found to shape the antitumor immune response and describe clinical efforts to use DNA repair biomarkers to guide use of immune-directed therapies.Significance: Only a subset of patients respond to immune checkpoint blockade, and reliable predictive biomarkers of response are needed to guide therapy decisions. DNA repair deficiency is common among tumors, and emerging experimental and clinical evidence suggests that features of genomic instability are associated with response to immune-directed therapies. Cancer Discov; 7(7); 675-93. ©2017 AACR.DNA-damaging agents are widely used in clinical oncology and exploit deficiencies in tumor DNA repair. Given the expanding role of immune checkpoint blockade as a therapeutic strategy, the interaction of tumor DNA damage with the immune system has recently come into focus, and it is now clear that the tumor DNA repair landscape has an important role in driving response to immune checkpoint blockade. Here, we summarize the mechanisms by which DNA damage and genomic instability have been found to shape the antitumor immune response and describe clinical efforts to use DNA repair biomarkers to guide use of immune-directed therapies.Significance: Only a subset of patients respond to immune checkpoint blockade, and reliable predictive biomarkers of response are needed to guide therapy decisions. DNA repair deficiency is common among tumors, and emerging experimental and clinical evidence suggests that features of genomic instability are associated with response to immune-directed therapies. Cancer Discov; 7(7); 675-93. ©2017 AACR. |
| Author | D'Andrea, Alan D Goldberg, Michael S Konstantinopoulos, Panagiotis A Mouw, Kent W |
| Author_xml | – sequence: 1 givenname: Kent W surname: Mouw fullname: Mouw, Kent W organization: Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts – sequence: 2 givenname: Michael S surname: Goldberg fullname: Goldberg, Michael S organization: Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts – sequence: 3 givenname: Panagiotis A surname: Konstantinopoulos fullname: Konstantinopoulos, Panagiotis A organization: Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts – sequence: 4 givenname: Alan D surname: D'Andrea fullname: D'Andrea, Alan D email: alan_dandrea@dfci.harvard.edu organization: Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, Massachusetts |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28630051$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj9FKwzAUhoNM3Jx7A5FeetOZkzZN491spw6Gguh1SdsTra5NTdqLvb0Rp3j44RwOHz98p2TSmQ4JOQe6BODpFQMuw5RJuszyEERIGUuOyOzvPfl3T8nCuXfqJ5Yxp-KETFmaRJRymJHr_GEV5KpVrxiorg6esFeNDW4a0yr7gdYFRgebth07M7yhVf3eI643ncMzcqzVzuHisOfk5Xb9nN2H28e7TbbahlUs4iGsKy19VKwppHWU6qiUkicgkQqEkrMKaAIJQ-7FRF0JTanHdcUTjCPO2Jxc_vT21nyO6IaibVyFu53q0IyuAAkgvBz7Ri8O6Fi2WBe9bbzGvvj1ZV8Kf1i2 |
| CitedBy_id | crossref_primary_10_1007_s00535_019_01620_7 crossref_primary_10_1080_17474124_2021_1853527 crossref_primary_10_1007_s10120_024_01542_1 crossref_primary_10_1158_0008_5472_CAN_18_1892 crossref_primary_10_1080_14737159_2019_1617702 crossref_primary_10_1111_pcmr_12943 crossref_primary_10_1111_imr_12738 crossref_primary_10_3389_fonc_2022_813253 crossref_primary_10_3390_cancers15133305 crossref_primary_10_1155_2023_8072369 crossref_primary_10_1177_1559325819891378 crossref_primary_10_3390_jpm13071045 crossref_primary_10_1186_s13073_019_0620_3 crossref_primary_10_1002_1878_0261_13526 crossref_primary_10_1002_cjp2_271 crossref_primary_10_1016_j_ccell_2025_06_011 crossref_primary_10_1016_S2468_1253_23_00207_8 crossref_primary_10_3389_fmed_2024_1233913 crossref_primary_10_3390_cancers15112955 crossref_primary_10_1186_s13045_019_0784_8 crossref_primary_10_1016_j_biopha_2022_113458 crossref_primary_10_1016_j_jbc_2023_102902 crossref_primary_10_3389_fimmu_2019_01713 crossref_primary_10_1158_1078_0432_CCR_22_2032 crossref_primary_10_3390_ijms231810231 crossref_primary_10_1038_s41467_021_27651_4 crossref_primary_10_1016_j_biomaterials_2024_122710 crossref_primary_10_1038_s41588_022_01108_w crossref_primary_10_1007_s11523_024_01032_5 crossref_primary_10_1038_s41586_019_1382_1 crossref_primary_10_3389_fphar_2020_01213 crossref_primary_10_3390_life11121318 crossref_primary_10_1007_s11912_018_0740_8 crossref_primary_10_1016_j_ijrobp_2018_07_2020 crossref_primary_10_1111_cei_13255 crossref_primary_10_2147_OTT_S283892 crossref_primary_10_1038_s43856_025_00860_4 crossref_primary_10_1016_j_pharmthera_2019_07_002 crossref_primary_10_1038_s41523_020_00197_2 crossref_primary_10_3389_fgene_2020_566244 crossref_primary_10_1634_theoncologist_2019_0636 crossref_primary_10_1634_theoncologist_2019_0637 crossref_primary_10_1038_s41598_020_77939_6 crossref_primary_10_1038_s41591_024_02808_y crossref_primary_10_1016_j_ctrv_2024_102785 crossref_primary_10_1158_1078_0432_CCR_21_0251 crossref_primary_10_3390_vaccines7030100 crossref_primary_10_1080_13543784_2021_1898586 crossref_primary_10_4251_wjgo_v15_i1_55 crossref_primary_10_3389_fimmu_2025_1600233 crossref_primary_10_1055_s_0040_1718904 crossref_primary_10_1158_1078_0432_CCR_24_1629 crossref_primary_10_1016_j_ijrobp_2020_05_011 crossref_primary_10_1016_j_ctrv_2019_08_003 crossref_primary_10_1111_jdv_15992 crossref_primary_10_3390_cancers14133094 crossref_primary_10_1007_s13402_018_00419_7 crossref_primary_10_3390_cancers10120492 crossref_primary_10_1016_j_jtho_2019_04_026 crossref_primary_10_1080_15257770_2023_2277194 crossref_primary_10_1186_s40425_019_0680_3 crossref_primary_10_1016_j_ijbiomac_2025_140902 crossref_primary_10_3390_cancers16233955 crossref_primary_10_1111_codi_17090 crossref_primary_10_1038_s41571_019_0179_3 crossref_primary_10_5858_arpa_2018_0584_CP crossref_primary_10_1007_s11938_022_00386_x crossref_primary_10_3389_fimmu_2022_856186 crossref_primary_10_3390_ijms20020429 crossref_primary_10_1016_j_cancergen_2025_09_002 crossref_primary_10_1007_s00262_020_02846_8 crossref_primary_10_1111_cas_15119 crossref_primary_10_3390_ph14090923 crossref_primary_10_1186_s13046_019_1089_z crossref_primary_10_3389_fgene_2021_635863 crossref_primary_10_1016_j_dnarep_2019_02_007 crossref_primary_10_3390_cancers17050880 crossref_primary_10_1186_s13550_020_00732_z crossref_primary_10_1136_jitc_2022_005041 crossref_primary_10_1002_pbc_27227 crossref_primary_10_1016_j_csbj_2023_09_021 crossref_primary_10_1172_JCI123319 crossref_primary_10_1158_2159_8290_CD_21_0832 crossref_primary_10_1016_j_semcancer_2018_05_006 crossref_primary_10_1038_s41467_019_10987_3 crossref_primary_10_1016_j_compbiomed_2025_110081 crossref_primary_10_1016_j_canlet_2019_10_027 crossref_primary_10_1002_1878_0261_12739 crossref_primary_10_1016_j_heliyon_2024_e24452 crossref_primary_10_3390_cancers13184520 crossref_primary_10_3389_fonc_2020_583314 crossref_primary_10_1097_CJI_0000000000000525 crossref_primary_10_1158_1078_0432_CCR_18_1821 crossref_primary_10_1038_s41591_019_0382_x crossref_primary_10_1177_1758835920944116 crossref_primary_10_1111_1440_1681_13056 crossref_primary_10_3390_ijms241512520 crossref_primary_10_1158_1078_0432_CCR_18_0968 crossref_primary_10_3390_ijms21010055 crossref_primary_10_1007_s12032_024_02504_4 crossref_primary_10_3390_ijms20123100 crossref_primary_10_3389_fimmu_2023_1127982 crossref_primary_10_3390_ijms22073485 crossref_primary_10_3390_cancers12030739 crossref_primary_10_1098_rsob_180037 crossref_primary_10_6061_clinics_2018_e429s crossref_primary_10_2147_OTT_S272563 crossref_primary_10_3389_fimmu_2019_00603 crossref_primary_10_3390_cancers13020241 crossref_primary_10_3892_ijo_2023_5534 crossref_primary_10_1111_1759_7714_70025 crossref_primary_10_1016_j_semcancer_2020_08_017 crossref_primary_10_1016_j_ebiom_2019_01_067 crossref_primary_10_1016_j_apsb_2021_01_003 crossref_primary_10_3390_ijms23147839 crossref_primary_10_3389_fcell_2021_756616 crossref_primary_10_1016_j_dnarep_2022_103409 crossref_primary_10_3390_cancers15153788 crossref_primary_10_3389_fonc_2020_00480 crossref_primary_10_1158_1078_0432_CCR_17_3509 crossref_primary_10_3389_fimmu_2021_829268 crossref_primary_10_1016_j_ebiom_2019_10_058 crossref_primary_10_3390_cancers13020277 crossref_primary_10_4251_wjgo_v16_i9_3875 crossref_primary_10_3389_fonc_2021_682932 crossref_primary_10_1038_s41416_022_01921_4 crossref_primary_10_1080_14737140_2021_1982699 crossref_primary_10_1186_s12957_023_03187_3 crossref_primary_10_1016_j_ebiom_2022_103897 crossref_primary_10_1182_bloodadvances_2021005017 crossref_primary_10_3390_ijms252212402 crossref_primary_10_3390_cancers12061502 crossref_primary_10_1002_cam4_5663 crossref_primary_10_1111_cas_15716 crossref_primary_10_2147_IJN_S466396 crossref_primary_10_1186_s40425_018_0463_2 crossref_primary_10_1016_j_actbio_2022_11_019 crossref_primary_10_1186_s12877_024_05201_z crossref_primary_10_1016_j_cll_2022_05_004 crossref_primary_10_1016_j_trsl_2018_02_001 crossref_primary_10_1016_j_biopha_2021_112470 crossref_primary_10_1016_j_urolonc_2020_11_021 crossref_primary_10_1038_s41577_023_00973_8 crossref_primary_10_1080_2162402X_2021_1936758 crossref_primary_10_1080_21655979_2021_1938470 crossref_primary_10_1016_j_dnarep_2019_05_005 crossref_primary_10_1073_pnas_1810409116 crossref_primary_10_1038_s41388_021_01744_2 crossref_primary_10_1016_j_ctrv_2019_04_003 crossref_primary_10_2174_0929867326666191004164041 crossref_primary_10_3390_biology10050385 crossref_primary_10_3390_ijms21051850 crossref_primary_10_1097_PPO_0000000000000499 crossref_primary_10_1016_j_addr_2022_114642 crossref_primary_10_1016_j_ygyno_2022_11_013 crossref_primary_10_2217_fon_2020_0730 crossref_primary_10_1186_s12885_023_10920_4 crossref_primary_10_1158_1078_0432_CCR_19_3841 crossref_primary_10_1111_cbdd_14156 crossref_primary_10_1136_jitc_2021_003580 crossref_primary_10_1002_advs_202308251 crossref_primary_10_3389_fonc_2021_688489 crossref_primary_10_3390_cancers13071713 crossref_primary_10_3390_ijms20174251 crossref_primary_10_1111_jcmm_16831 crossref_primary_10_2147_ITT_S253581 crossref_primary_10_3390_ijms24044044 crossref_primary_10_1016_j_clon_2023_05_015 crossref_primary_10_1186_s40425_019_0805_8 crossref_primary_10_3389_fonc_2020_00570 crossref_primary_10_3390_ijms19061794 crossref_primary_10_17116_medtech20244601191 crossref_primary_10_1158_2326_6066_CIR_18_0277 crossref_primary_10_1200_JCO_2018_78_2425 crossref_primary_10_1136_jitc_2024_010926 crossref_primary_10_2217_bmm_2020_0575 crossref_primary_10_1038_s41598_025_91102_z crossref_primary_10_1111_liv_14102 crossref_primary_10_1016_j_ijrobp_2021_07_1708 crossref_primary_10_3389_fimmu_2022_875648 crossref_primary_10_1038_s41388_020_01398_6 crossref_primary_10_1016_j_semcancer_2022_04_001 crossref_primary_10_3390_cancers15041076 crossref_primary_10_12968_hmed_2024_0375 crossref_primary_10_1007_s12032_023_02021_w crossref_primary_10_2217_fon_2020_0707 crossref_primary_10_1016_j_ebiom_2023_104801 crossref_primary_10_3389_fphar_2019_00798 crossref_primary_10_1186_s40425_019_0619_8 crossref_primary_10_3390_cancers13081762 crossref_primary_10_1038_s41467_024_48423_w crossref_primary_10_1016_j_intimp_2022_108738 crossref_primary_10_1111_1759_7714_15408 crossref_primary_10_1016_j_dld_2023_08_050 crossref_primary_10_1186_s12885_024_12254_1 crossref_primary_10_3390_ijms222312916 crossref_primary_10_1002_path_5829 crossref_primary_10_1016_j_semcancer_2020_01_003 crossref_primary_10_1016_j_yao_2021_02_010 crossref_primary_10_3389_fcell_2021_641891 crossref_primary_10_1097_MD_0000000000037966 crossref_primary_10_1200_JCO_19_00347 crossref_primary_10_3389_fonc_2021_670927 crossref_primary_10_1016_j_critrevonc_2023_104058 crossref_primary_10_1016_j_canlet_2023_216595 crossref_primary_10_1016_j_canlet_2023_216594 crossref_primary_10_1016_j_clon_2018_05_008 crossref_primary_10_1038_s41598_023_38060_6 crossref_primary_10_1186_s40425_018_0472_1 crossref_primary_10_3389_fonc_2023_1210673 crossref_primary_10_1038_s41421_023_00614_3 crossref_primary_10_1136_jitc_2020_001065 crossref_primary_10_3390_ijms23073871 crossref_primary_10_1007_s11912_021_01038_6 crossref_primary_10_1016_j_tibs_2018_09_004 crossref_primary_10_2217_fon_2018_0330 crossref_primary_10_1038_s41698_023_00428_2 crossref_primary_10_1146_annurev_med_060116_022926 crossref_primary_10_1186_s12916_019_1326_5 crossref_primary_10_1109_TNANO_2018_2821164 crossref_primary_10_1158_1078_0432_CCR_22_0791 crossref_primary_10_1111_cas_14570 crossref_primary_10_1097_PPO_0000000000000560 crossref_primary_10_3389_fcell_2022_813457 crossref_primary_10_1158_1078_0432_CCR_19_0899 crossref_primary_10_1158_0008_5472_CAN_20_1710 crossref_primary_10_3390_ijms26083743 crossref_primary_10_1073_pnas_2208506119 crossref_primary_10_1186_s12935_021_02229_8 crossref_primary_10_1136_jitc_2021_003195 crossref_primary_10_1002_cam4_4725 crossref_primary_10_1038_s41416_020_0834_6 crossref_primary_10_3390_cancers12102762 crossref_primary_10_3390_cancers13061300 crossref_primary_10_2174_0929867327666200224102309 crossref_primary_10_1177_1758835918786658 crossref_primary_10_1016_j_tranon_2020_100888 crossref_primary_10_1016_j_aquatox_2025_107577 crossref_primary_10_1373_clinchem_2019_303644 crossref_primary_10_3389_fgene_2022_886170 crossref_primary_10_3390_ijms22126532 crossref_primary_10_1093_jjco_hyac183 crossref_primary_10_1016_j_envpol_2021_118095 crossref_primary_10_1016_j_tranon_2019_11_002 crossref_primary_10_1002_mco2_103 crossref_primary_10_1172_JCI175369 crossref_primary_10_1186_s13073_022_01129_4 crossref_primary_10_1016_j_ctrv_2021_102256 crossref_primary_10_1093_mutage_gez049 crossref_primary_10_1007_s11892_019_1169_7 crossref_primary_10_1186_s12935_023_02869_y crossref_primary_10_3390_cancers12071828 crossref_primary_10_1002_cam4_3649 crossref_primary_10_1097_CJI_0000000000000279 crossref_primary_10_1007_s12325_019_01051_z crossref_primary_10_1186_s12935_022_02597_9 crossref_primary_10_1080_07853890_2023_2200033 crossref_primary_10_1002_jcla_24141 crossref_primary_10_1007_s00280_019_03878_3 crossref_primary_10_1158_1078_0432_CCR_18_0468 crossref_primary_10_1016_j_jbc_2021_100721 crossref_primary_10_1007_s00432_022_03941_2 crossref_primary_10_1186_s12967_020_02667_4 crossref_primary_10_1016_j_clcc_2020_02_003 crossref_primary_10_1111_1754_9485_13413 crossref_primary_10_1159_000506775 crossref_primary_10_48130_git_0025_0002 crossref_primary_10_1016_j_humpath_2017_07_014 crossref_primary_10_2217_fon_2020_0215 crossref_primary_10_3390_cancers12071724 crossref_primary_10_3389_fimmu_2022_1106644 crossref_primary_10_3390_pharmaceutics15092241 crossref_primary_10_1080_07357907_2023_2167209 crossref_primary_10_1002_cac2_12539 crossref_primary_10_3390_diagnostics11010084 crossref_primary_10_1038_s41598_024_52110_7 crossref_primary_10_3390_cancers15245841 crossref_primary_10_1016_j_jtho_2024_10_021 crossref_primary_10_1080_14737140_2020_1807334 crossref_primary_10_1038_s41568_020_0265_y crossref_primary_10_1007_s10147_019_01519_6 crossref_primary_10_1016_j_ygyno_2019_02_011 crossref_primary_10_1186_s13046_022_02469_0 crossref_primary_10_1155_2019_4325105 crossref_primary_10_1016_j_ctarc_2020_100179 crossref_primary_10_1002_cam4_71065 crossref_primary_10_1016_j_ygyno_2025_07_016 crossref_primary_10_1016_j_tips_2019_01_005 crossref_primary_10_3390_ijms241411695 crossref_primary_10_1038_s41416_018_0017_x crossref_primary_10_1038_s43018_023_00617_9 crossref_primary_10_7554_eLife_82786 crossref_primary_10_1038_s41392_020_0116_z crossref_primary_10_1080_14656566_2022_2106782 crossref_primary_10_1016_j_cllc_2022_01_005 crossref_primary_10_1186_s12885_020_6605_1 crossref_primary_10_1186_s12885_023_10831_4 crossref_primary_10_3389_fonc_2021_634920 crossref_primary_10_1038_s41420_021_00417_z crossref_primary_10_3892_mco_2021_2369 crossref_primary_10_1038_s41598_022_23788_4 crossref_primary_10_1186_s13073_021_00988_7 crossref_primary_10_1016_j_gene_2019_144323 crossref_primary_10_1136_jitc_2024_010548 crossref_primary_10_3389_fonc_2023_1159557 crossref_primary_10_1007_s13691_024_00685_3 crossref_primary_10_1093_gigascience_giae105 crossref_primary_10_3390_cancers14194874 crossref_primary_10_1155_2018_5068701 crossref_primary_10_1186_s40001_024_01672_3 crossref_primary_10_1186_s40364_020_00202_7 crossref_primary_10_7717_peerj_10128 crossref_primary_10_1186_s12916_021_02068_4 crossref_primary_10_1186_s40364_025_00814_x crossref_primary_10_1007_s12032_022_01782_0 crossref_primary_10_1093_annonc_mdz192 crossref_primary_10_1055_a_1475_4335 crossref_primary_10_1007_s10147_023_02351_9 crossref_primary_10_1093_annonc_mdz079 crossref_primary_10_3390_ijms222312761 crossref_primary_10_2174_1381612825666190319114641 crossref_primary_10_3390_ijms231911649 crossref_primary_10_1001_jamanetworkopen_2019_11895 crossref_primary_10_1158_0008_5472_CAN_19_0761 crossref_primary_10_1038_s41416_025_03032_2 crossref_primary_10_1186_s12885_020_06817_1 crossref_primary_10_1186_s13046_025_03519_z crossref_primary_10_1200_JCO_2017_75_7740 crossref_primary_10_1158_1078_0432_CCR_18_2581 crossref_primary_10_3390_cancers15051619 crossref_primary_10_1634_theoncologist_2019_0034 crossref_primary_10_3390_ijms21176176 crossref_primary_10_3389_fonc_2020_539527 crossref_primary_10_1158_1078_0432_CCR_19_3529 crossref_primary_10_1002_aac2_12047 crossref_primary_10_1016_j_biomaterials_2019_119377 crossref_primary_10_1007_s10120_024_01523_4 crossref_primary_10_3389_fmolb_2020_608368 crossref_primary_10_3389_fonc_2021_708294 crossref_primary_10_3390_ijms23063238 crossref_primary_10_3389_fcell_2022_772701 crossref_primary_10_1016_j_hoc_2021_02_006 crossref_primary_10_1016_j_ctrv_2018_09_002 crossref_primary_10_1111_1759_7714_14902 crossref_primary_10_3389_fonc_2020_549777 crossref_primary_10_1177_1758835919897537 crossref_primary_10_1177_1758835920958354 crossref_primary_10_1016_j_biopha_2023_114770 crossref_primary_10_1038_s41698_023_00442_4 crossref_primary_10_3390_genes11090990 crossref_primary_10_2217_fon_2017_0405 crossref_primary_10_3233_BLC_200289 crossref_primary_10_3390_cancers11111797 crossref_primary_10_1158_2159_8290_CD_20_1503 crossref_primary_10_1177_17588359231163807 crossref_primary_10_1016_j_hoc_2021_02_008 crossref_primary_10_3390_biom13101480 crossref_primary_10_1007_s00432_022_04139_2 crossref_primary_10_1136_gutjnl_2018_317624 crossref_primary_10_3389_fgene_2022_1008644 crossref_primary_10_1007_s10555_023_10121_2 crossref_primary_10_1016_j_jid_2021_07_166 crossref_primary_10_3389_fonc_2021_648687 crossref_primary_10_1016_j_ymthe_2023_03_026 crossref_primary_10_1007_s10555_021_09983_1 crossref_primary_10_3390_cancers12113129 crossref_primary_10_1158_0008_5472_CAN_18_1814 crossref_primary_10_1002_cam4_2849 crossref_primary_10_3389_fonc_2021_638873 crossref_primary_10_1146_annurev_cancerbio_030617_050502 crossref_primary_10_1186_s13014_025_02711_x crossref_primary_10_3389_fonc_2021_727027 crossref_primary_10_3390_ijms24087640 crossref_primary_10_3390_pharmaceutics12060524 crossref_primary_10_1186_s13046_023_02729_7 crossref_primary_10_3390_ijms21176087 crossref_primary_10_3389_fonc_2019_01465 crossref_primary_10_1016_j_semcancer_2019_12_005 crossref_primary_10_1080_2162402X_2022_2044103 crossref_primary_10_1136_jitc_2022_005026 crossref_primary_10_3389_fgene_2022_919599 crossref_primary_10_1016_j_biopha_2020_110204 crossref_primary_10_1155_2022_8736575 crossref_primary_10_3389_fmicb_2025_1602217 crossref_primary_10_3389_fmolb_2022_1073797 crossref_primary_10_1016_j_tranon_2023_101629 crossref_primary_10_1080_2162402X_2018_1457602 crossref_primary_10_1002_ddr_22155 crossref_primary_10_1158_2159_8290_CD_20_0522 crossref_primary_10_3390_vaccines9050422 crossref_primary_10_1158_1078_0432_CCR_18_1851 crossref_primary_10_3390_ijms26125849 crossref_primary_10_1016_j_drup_2024_101115 crossref_primary_10_1016_j_semcancer_2021_08_011 crossref_primary_10_1186_s12967_024_05583_z crossref_primary_10_3389_fonc_2018_00185 crossref_primary_10_1007_s11356_021_16726_w crossref_primary_10_3389_fimmu_2021_661115 crossref_primary_10_1016_j_ebiom_2022_104092 crossref_primary_10_1038_s43018_020_00139_8 crossref_primary_10_1186_s13045_021_01218_8 crossref_primary_10_1200_EDBK_238473 crossref_primary_10_1002_mc_23384 crossref_primary_10_1038_s41467_024_51242_8 crossref_primary_10_1186_s40364_022_00427_8 crossref_primary_10_1097_CJI_0000000000000478 crossref_primary_10_1016_j_isci_2025_112882 crossref_primary_10_3390_cancers13236027 crossref_primary_10_3389_fimmu_2025_1554499 crossref_primary_10_3390_cancers13215466 crossref_primary_10_3390_cancers14051248 crossref_primary_10_1177_1756287218814100 crossref_primary_10_3390_cancers14051245 crossref_primary_10_1136_jitc_2019_000319 crossref_primary_10_1053_j_seminoncol_2021_01_005 crossref_primary_10_3390_cancers13215471 crossref_primary_10_3389_fonc_2021_683419 crossref_primary_10_1002_advs_202001041 crossref_primary_10_1016_j_jconrel_2021_01_036 crossref_primary_10_3390_cancers14164050 crossref_primary_10_3390_cancers12082098 crossref_primary_10_1007_s11864_024_01243_y crossref_primary_10_3390_ijms24065332 crossref_primary_10_1016_j_nec_2020_06_011 crossref_primary_10_1016_S1470_2045_18_30693_4 crossref_primary_10_3390_ijms19041255 crossref_primary_10_3389_fgene_2022_850888 crossref_primary_10_1007_s42764_020_00023_w crossref_primary_10_1146_annurev_med_042320_025136 crossref_primary_10_1177_1758835918816281 crossref_primary_10_1111_bcp_14355 crossref_primary_10_1146_annurev_cancerbio_030518_055914 crossref_primary_10_3390_ijms25052479 crossref_primary_10_1016_j_retram_2025_103494 crossref_primary_10_1146_annurev_cancerbio_030419_033604 crossref_primary_10_1186_s12920_023_01459_1 crossref_primary_10_1016_j_cell_2018_08_065 crossref_primary_10_3390_ijms22147583 crossref_primary_10_1186_s11658_024_00568_8 crossref_primary_10_1038_s41568_021_00386_6 crossref_primary_10_1038_s41523_018_0061_y crossref_primary_10_1038_s41423_018_0086_z crossref_primary_10_3389_fonc_2021_695770 crossref_primary_10_3389_fonc_2022_795129 |
| ContentType | Journal Article |
| Copyright | 2017 American Association for Cancer Research. |
| Copyright_xml | – notice: 2017 American Association for Cancer Research. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1158/2159-8290.CD-17-0226 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2159-8290 |
| ExternalDocumentID | 28630051 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: NCATS NIH HHS grantid: KL2 TR001100 – fundername: NIDDK NIH HHS grantid: R56 DK043889 – fundername: NCI NIH HHS grantid: P50 CA168504 – fundername: NIDDK NIH HHS grantid: R01 DK043889 – fundername: NHLBI NIH HHS grantid: R37 HL052725 – fundername: NHLBI NIH HHS grantid: P01 HL048546 – fundername: NHLBI NIH HHS grantid: R01 HL052725 |
| GroupedDBID | --- 53G 5VS ADBBV ADCOW AENEX AFHIN AFUMD ALMA_UNASSIGNED_HOLDINGS BR6 BTFSW CGR CUY CVF EBS ECM EIF EJD H13 KQ8 NPM OK1 RCR RHI 7X8 |
| ID | FETCH-LOGICAL-c474t-dcf9cf9a4f018d38f3b995619e07e1b52c106162e51587dc7f00f9afc56e43522 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 531 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000404970800021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2159-8290 |
| IngestDate | Sun Aug 24 04:06:09 EDT 2025 Thu Apr 03 07:07:46 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| License | 2017 American Association for Cancer Research. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c474t-dcf9cf9a4f018d38f3b995619e07e1b52c106162e51587dc7f00f9afc56e43522 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | http://doi.org/10.1158/2159-8290.CD-17-0226 |
| PMID | 28630051 |
| PQID | 1911700422 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1911700422 pubmed_primary_28630051 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-07-01 |
| PublicationDateYYYYMMDD | 2017-07-01 |
| PublicationDate_xml | – month: 07 year: 2017 text: 2017-07-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cancer discovery |
| PublicationTitleAlternate | Cancer Discov |
| PublicationYear | 2017 |
| SSID | ssj0000494507 |
| Score | 2.6467447 |
| SecondaryResourceType | review_article |
| Snippet | DNA-damaging agents are widely used in clinical oncology and exploit deficiencies in tumor DNA repair. Given the expanding role of immune checkpoint blockade... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 675 |
| SubjectTerms | Antineoplastic Agents - immunology Antineoplastic Agents - therapeutic use Biomarkers, Tumor - genetics Biomarkers, Tumor - immunology DNA Damage - drug effects DNA Damage - immunology DNA Repair - drug effects DNA Repair - immunology Genomic Instability - drug effects Genomic Instability - immunology Humans Immunotherapy - adverse effects Neoplasms - genetics Neoplasms - immunology Neoplasms - therapy |
| Title | DNA Damage and Repair Biomarkers of Immunotherapy Response |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28630051 https://www.proquest.com/docview/1911700422 |
| Volume | 7 |
| WOSCitedRecordID | wos000404970800021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvInhdTTab7MaL1Naih4YeFHoL-4QemtSmCv57Z7dpPQmCEHIIEwjDZObbmflmELohggsR6RSzyFJMWSgxSMbYKojnMuWppNovm2B5zkejbNgk3OqmrXLpE72j1pVyOfI7OFe4UXKUkIfpO3Zbo1x1tVmhsY5aMUAZZ9VsxFc5Fjf7JPGMaQhsGXY1w4Y9FyX8bvXsttvD4KshmqW_40wfb_q7__3SPbTTIM2gszCNfbRmygO0NWhq6Yfovpd3gp6YgEMJRKkDgOJiPAsex9XEtezM6qCywYujjzQkrS8Q8Q215gi99Z9eu8-42aSAFWV0jrWyGVyC2jDiOuY2lp7RmpmQmUgmRLmTYUoMoBvOtGI2DEHcqiQ11EG0Y7RRVqU5RQFRMtZZKkPBLJXWcCOIMDbTgGuUllkbXS-1UoCluvKDKE31URc_emmjk4Vqi-lipEZBuBv9lURnf3j7HG0TF1t9z-wFaln4T80l2lSf83E9u_ImAPd8OPgGONu5Mw |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=DNA+Damage+and+Repair+Biomarkers+of+Immunotherapy+Response&rft.jtitle=Cancer+discovery&rft.au=Mouw%2C+Kent+W&rft.au=Goldberg%2C+Michael+S&rft.au=Konstantinopoulos%2C+Panagiotis+A&rft.au=D%27Andrea%2C+Alan+D&rft.date=2017-07-01&rft.issn=2159-8290&rft.eissn=2159-8290&rft.volume=7&rft.issue=7&rft.spage=675&rft_id=info:doi/10.1158%2F2159-8290.CD-17-0226&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2159-8290&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2159-8290&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2159-8290&client=summon |